Pharmacist nets $31 million from whistleblower cases
November 8th 2013For years, Bernie Lisitza owned small pharmacies in the Chicago area. He eventually traded his dual role as owner and pharmacist and went to work for Omnicare, which dispenses prescriptions for nursing homes throughout the country.
Health Choices coalition supports FSA bill for OTC products
November 8th 2013The National Association of Chain Drug Stores and the National Community Pharmacists Association have endorsed legislation that would restore the ability of consumers to purchase OTC medications using pre-tax dollars from flexible spending accounts and health savings accounts without obtaining a doctor’s endorsement.
How long should antiplatelet therapy last following stent implantation?
November 5th 2013Short-term dual antiplatelet therapy was as effective as long-term therapy for patients who underwent percutaneous coronary intervention (PCI) with a second-generation drug-eluting stent, according to an online study published in JAMA.
Investigational tiotropium reduces exacerbations in severe asthma cases
November 5th 2013Once-daily dosing of the investigational drug tiotropium helped to improve lung function over 24 hours in individuals with severe asthma, according to data presented at the 2013 American College of Chest Physicians annual meeting (CHEST 2013) in Chicago.
Under breakthrough therapy designation, FDA approves chronic lymphocytic leukemia drug
November 1st 2013FDA has approved obinutuzumab (Gazyva, Genentech, a member of the Roche Group), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of patients with previously untreated chronic lymphocytic leukemia.
Allopurinol alone found inadequate for gout control
October 31st 2013Allopurinol, considered the standard of care for gout, may be inadequate to lower uric acid levels in patients with gout, according to new safety and efficacy data from a large study presented at the American College of Rheumatology 2013 annual meeting recently in San Diego, Calif.
Bullying, disrespect rampant in healthcare settings
October 29th 2013Rude and disrespectful behavior including bullying and intimidation is a big problem in healthcare workplaces that erodes professional communication essential to patient safety, according to a recent study by the Institute for Safe Medication Practices.
FDA approves extended-release, single-entity hydrocodone product
October 29th 2013FDA has approved hydrocodone bitartrate extended-release capsules (Zohydro ER, Zogenix) for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate.
Study highlights need to address anaphylaxis prevention
October 24th 2013Severe life-threatening allergic reactions are more common than many thought. Anaphylaxis very likely occurs in nearly 1 in 50 Americans (1.6%), and the rate is probably higher, close to 1 in 20 (5.1%), according to a study published in the Journal of Allergy and Clinical Immunology.
FDA calls for reclassification of hydrocodone products to Schedule II
October 24th 2013The FDA is recommending to the U.S. Department of Health and Human Services (HHS) that hydrodone combination products, such as Vicodin, be reclassified as a Schedule II product, placing tighter controls on the pain medications. Hydrocodone is currently a Schedule III drug, according to an FDA announcement.